Bone Biologics Corp Warrants
BBLGW
2 hedge funds and large institutions have $400K invested in Bone Biologics Corp Warrants in 2026 Q2 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, 1 reducing their positions, and closing their positions.
0% more funds holding
Funds holding: 2 → 2 (0)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
42% less capital invested
Capital invested by funds: $690K → $400K (-$290K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$1.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$55.2K |
BBLGW Hedge Fund Activity: Q2 2026 in Review
2 of the 8,343 institutional investors tracked by Wall St. Rank reported a position in Bone Biologics Corp Warrants (BBLGW) for Q2 2026, worth a combined $400K — down 42% from $690K a quarter earlier.
Fund positioning in BBLGW was balanced in Q2 2026: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 1 trimmed.
The largest buyer was UBS Group, adding an estimated $1.5K. The largest seller was Citadel Advisors, cutting an estimated $55.2K.
- 2 institutional investors held Bone Biologics Corp Warrants (BBLGW) as of Q2 2026, unchanged from Q1 2026.
- Funds reported $400K of Bone Biologics Corp Warrants stock for Q2 2026, down 42% quarter-over-quarter.
- 0 funds opened new Bone Biologics Corp Warrants positions in Q2 2026 and 0 closed out.
- The largest Bone Biologics Corp Warrants buyer in Q2 2026 was UBS Group, an estimated $1.5K added.
- The largest Bone Biologics Corp Warrants seller in Q2 2026 was Citadel Advisors, an estimated $55.2K sold.
Based on aggregated 13F filings for Q2 2026.